Will Aptose Biosciences Incorporated (NASDAQ:APTO) Run Out of Steam Soon? Short Interest Is Down

October 13, 2017 - By Clifton Ray

 Will Aptose Biosciences Incorporated (NASDAQ:APTO) Run Out of Steam Soon? Short Interest Is Down

The stock of Aptose Biosciences Incorporated (NASDAQ:APTO) registered a decrease of 7.06% in short interest. APTO’s total short interest was 947,600 shares in October as published by FINRA. Its down 7.06% from 1.02 million shares, reported previously. With 148,400 shares average volume, it will take short sellers 6 days to cover their APTO’s short positions. The short interest to Aptose Biosciences Incorporated’s float is 6.02%.

The stock decreased 0.71% or $0.01 on October 13, reaching $1.39. About 127,953 shares traded. Aptose Biosciences Inc (NASDAQ:APTO) has declined 60.81% since October 13, 2016 and is downtrending. It has underperformed by 77.51% the S&P500.

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company has market cap of $33.06 million. The Firm is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. It currently has negative earnings. The Company’s product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Aptose Biosciences Inc (NASDAQ:APTO) Ratings Coverage

Among 4 analysts covering Aptose Biosciences (NASDAQ:APTO), 3 have Buy rating, 0 Sell and 1 Hold. Therefore 75% are positive. Aptose Biosciences had 11 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, November 20 by Roth Capital. TH Capital downgraded the stock to “Neutral” rating in Friday, November 20 report. RBC Capital Markets maintained the shares of APTO in report on Wednesday, November 16 with “Outperform” rating. The stock has “Hold” rating by Zacks on Friday, August 7. H.C. Wainwright upgraded the stock to “Buy” rating in Thursday, September 7 report. The rating was maintained by RBC Capital Markets on Wednesday, November 11 with “Outperform”. The stock has “Hold” rating by H.C. Wainwright on Thursday, June 8. On Wednesday, August 9 the stock rating was maintained by H.C. Wainwright with “Hold”. Roth Capital upgraded Aptose Biosciences Inc (NASDAQ:APTO) rating on Monday, June 13. Roth Capital has “Buy” rating and $8 target.

More notable recent Aptose Biosciences Inc (NASDAQ:APTO) news were published by: Globenewswire.com which released: “Aptose Biosciences Provides Update on APTO-253 Development” on December 29, 2016, also Globenewswire.com with their article: “Aptose Reports Results for the Second Quarter Ended June 30, 2017” published on August 08, 2017, Seekingalpha.com published: “Aptose Looking Toward Human Studies” on September 20, 2017. More interesting news about Aptose Biosciences Inc (NASDAQ:APTO) were released by: Globenewswire.com and their article: “Aptose Prioritizes Development of CG’806 First-in Class FLT3/BTK Inhibitor” published on January 23, 2017 as well as Seekingalpha.com‘s news article titled: “Aptose Biosciences’ (APTO) CEO William Rice on Q2 2017 Results – Earnings Call …” with publication date: August 12, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.